DOCSLIB.ORG

2021 Senate Bill 20

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

21.183.13 96th Legislative Session 400 2021 South Dakota Legislature Senate Bill 20 ENROLLED AN ACT ENTITLED An Act to place certain substances on the controlled substances schedule and to declare an emergency. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA: Section 1. That § 34-20B-12 be AMENDED. 34-20B-12. Specific substances included in Schedule I. Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, is included in Schedule I, unless specifically excepted, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: (1) Acetylmethadol; (2) Allylprodine; (3) Alphacetylmethadol, except levo-alphacetylmethadol, also known as levo-alpha- acetylmethadol, levomethadyl acetate or LAAM; (4) Alphameprodine; (5) Alphamethadol; (6) Benzethidine; (7) Betacetylmethadol; (8) Betameprodine; (9) Betamethadol; (10) Betaprodine; (11) Clonitazene; (12) Dextromoramide; (13) Diampromide; (14) Diethyliambutene; (15) Dimenoxadol; (16) Dimepheptanol; 21.183.13 2 400 (17) Dimethyliambutene; (18) Dioxaphetyl butyrate; (19) Dipipanone; (20) Ethylmethylthiambutene; (21) Etonitazene; (22) Etoxeridine; (23) Furethidine; (24) Hydroxypethidine; (25) Ketobemidone; (26) Levomoramide; (27) Levophenacylmorphan; (28) Mecloqualone; (29) Morpheridine; (30) Noracymethadol; (31) Norlevorphanol; (32) Normethadone; (33) Norpipanone; (34) Phenadoxone; (35) Phenampromide; (36) Phenomorphan; (37) Phenoperidine; (38) Piritramide; (39) Proheptazine; (40) Properidine; (41) Racemoramide; (42) Trimeperidine; (43) Methaqualone; (44) N-benzylpiperazine; (45) 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide, W-18; and (46) N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1- amine, also known as isotonitazene. Section 2. That § 34-20B-13 be AMENDED. SB20 ENROLLED 21.183.13 3 400 34-20B-13. Opium derivatives and opiates included in Schedule I. Any of the following opium derivatives and opiates, their salts, isomers, esters, ethers, and salts of isomers, esters, and ethers, is included in Schedule I, unless specifically excepted, whenever the existence of such salts, isomers, esters, ethers, and salts of isomers, esters, and ethers is possible within the specific chemical designation: (1) Acetylcodone; (2) Benzylmorphine; (3) Codeine methylbromide; (4) Codeine-N-Oxide; (5) Desomorphine; (6) Drotebanol; (7) Heroin; (8) Hydromorphinol; (9) Methydesorphine; (10) Methylhydromorphine; (11) Morphine methylbromide; (12) Morphine methylsulfonate; (13) Morphine-N-Oxide; (14) Myrophine; (15) Nicocodeine; (16) Nicomorphine; (17) Normorphine; (18) Thebacon; (19) 3-Methylfentanyl; (20) Fentanyl analogs. Any substituted derivatives of fentanyl unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, that is structurally related to fentanyl by modification in any one or more of the following ways: (a) By replacement of the phenyl portion of the phenethyl group by any monocycle whether or not further substituted in or on the monocycle; (b) By substitution in or on or replacement of the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups; (c) By substitution in or on the piperadine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, phenyl, substituted phenyl, or nitro groups; SB20 ENROLLED 21.183.13 4 400 (d) By replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or (e) By the replacement of the N-propionyl group by another acyl group. Some trade and other names: N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl); N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl fentanyl); N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl, acryloylfentanyl); N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho- fluorofentanyl or 2-fluorofentanyl); N-(1-phenethylpiperidin-4-yl)-N- phenyltetrahydrofuran-2-carboxamide (tetrahydrofuranyl fentanyl); 2-methoxy-N-(1- phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl fentanyl); N-(1- phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (cyclopropyl fentanyl), N- phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide (valeryl fentanyl); N-(1- phenethylpiperidin-4-yl)-N-phenylbutyramide (butyrl fentanyl); N-[1-(2-hydroxy-2- thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide (Beta-Hydroxythiofentanyl); N- (4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para-fluorobutyryl fentanyl); N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para- methoxybutyryl fentanyl); N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4- yl)isobutyramide (para-chloroisobutyryl fentanyl); N-(1-phenethylpiperidin-4-yl)-N- phenylisobutyramide (isobutyryl fentanyl); N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopentanecarboxamide (cyclopentyl fentanyl); N-(2-fluorophenyl)-2-methoxy- N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil); N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide (para-fluoroisobutyryl fentanyl); (E)-N-(1- phenethylpiperidin-4-yl)-N-phenylbut-2-enamide (Crotonyl fentanyl); (21) 1-Methyl-4-phenyl-4-propionoxypiperidine; (22) 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine; (23) 3,4-dichloro-N[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700); (24) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45); (25) 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide (AH-7921); (26) 2-(2,4-dichlorophenyl)-N-2-(dimethylamino)cyclohexyl)-N-methylacetamide (U- 48800); (27) Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (U- 49900); (28) N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide (Methylenedioxy-U-47700); SB20 ENROLLED 21.183.13 5 400 (29) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropylbenzamide (Isopropyl- U-47700); (30) 1-(1,2-Diphenylethyl)piperidine (Diphenidine); (31) N-Ethyl-1,2-diphenylethylamine (Ephenidine); and (32) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol- 2-one (Brorphine). Section 3. That § 34-20B-14 be AMENDED. 34-20B-14. Hallucinogenic substances sincluded in Schedule I. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Bufotenine; (2) Diethyltryptamine (DET); (3) Dimethyltryptamine (DMT); (4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT); (5) 5-methoxy-3, 4-methylenedioxy amphetamine; (6) 4-bromo-2, 5-dimethoxyamphetamine; (7) 4-methoxyamphetamine; (8) 4-methoxymethamphetamine; (9) 4-methyl-2, 5-dimethoxyamphetamine; (10) Hashish and hash oil; (11) Ibogaine; (12) Lysergic acid diethylamide; (13) Mescaline; (14) N-ethyl-3-piperidyl benzilate; (15) N-methyl-3-piperidyl benzilate; (16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP); (17) Peyote, except that when used as a sacramental in services of the Native American church in a natural state which is unaltered except for drying or curing and cutting or slicing, it is hereby excepted; (18) Psilocybin; (19) Psilocyn; SB20 ENROLLED 21.183.13 6 400 (20) Tetrahydrocannabinol, other than that which occurs in industrial hemp as defined in § 38-35-1 or marijuana in its natural and unaltered state, including any compound, except nabilone or compounds listed under a different schedule, structurally derived from 6,6 dimethyl-benzo[c]chromene by substitution at the 3- position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups, whether or not the compound is further modified in any of the following ways: (a) By partial to complete saturation of the C-ring; or (b) By substitution at the 1-position with a hydroxyl or methoxy group; or (c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl group; or (d) By modification of the possible 3-alkyl group with a 1,1 dimethyl moiety, a 1,1 cyclic moiety, an internal methylene group, an internal acetylene group, or a terminal halide, cyano, azido, or dimethylcarboxamido group. Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC; AM- 087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243; HU-336; (21) 3, 4, 5-trimethoxy amphetamine; (22) 3, 4-methylenedioxy amphetamine; (23) 3-methoxyamphetamine; (24) 2, 5-dimethoxyamphetamine; (25) 2-methoxyamphetamine; (26) 2-methoxymethamphetamine; (27) 3-methoxymethamphetamine; (28) Phencyclidine; (29) 3, 4-methylenedioxymethamphetamine (MDMA); (30) 3, 4-methylenedioxy-N-ethylamphetamine; (31) N-hydroxy-3, 4-methylenedioxyamphetamine; (32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline); (33) 2,5 Dimethoxy-4-ethylamphetamine; (34) N,N-Dimethylamphetamine; (35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; (36) Aminorex; (37) Cathinone and other variations, defined as any compound, material, mixture, preparation or other product unless listed in another schedule or an approved FDA drug (e.g. buproprion, pyrovalerone), structurally derived from 2-aminopropan-1- SB20 ENROLLED 21.183.13 7 400 one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further
Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
  • FSI-D-16-00226R1 Title

    FSI-D-16-00226R1 Title

    Elsevier Editorial System(tm) for Forensic Science International Manuscript Draft Manuscript Number: FSI-D-16-00226R1 Title: An overview of Emerging and New Psychoactive Substances in the United Kingdom Article Type: Review Article Keywords: New Psychoactive Substances Psychostimulants Lefetamine Hallucinogens LSD Derivatives Benzodiazepines Corresponding Author: Prof. Simon Gibbons, Corresponding Author's Institution: UCL School of Pharmacy First Author: Simon Gibbons Order of Authors: Simon Gibbons; Shruti Beharry Abstract: The purpose of this review is to identify emerging or new psychoactive substances (NPS) by undertaking an online survey of the UK NPS market and to gather any data from online drug fora and published literature. Drugs from four main classes of NPS were identified: psychostimulants, dissociative anaesthetics, hallucinogens (phenylalkylamine-based and lysergamide-based materials) and finally benzodiazepines. For inclusion in the review the 'user reviews' on drugs fora were selected based on whether or not the particular NPS of interest was used alone or in combination. NPS that were use alone were considered. Each of the classes contained drugs that are modelled on existing illegal materials and are now covered by the UK New Psychoactive Substances Bill in 2016. Suggested Reviewers: Title Page (with authors and addresses) An overview of Emerging and New Psychoactive Substances in the United Kingdom Shruti Beharry and Simon Gibbons1 Research Department of Pharmaceutical and Biological Chemistry UCL School of Pharmacy
  • DEPARTMENT of JUSTICE Drug Enforcement

    DEPARTMENT of JUSTICE Drug Enforcement

    This document is scheduled to be published in the Federal Register on 08/03/2021 and available online at DEPARTMENT OF JUSTICEfederalregister.gov/d/2021-16499, and on govinfo.gov Drug Enforcement Administration Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation [Docket No. DEA-873] AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. SUMMARY: Cerilliant Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on June, 24, 2021, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled Substance Drug Code Schedule 3-Fluoro-N-methylcathinone
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Synthetic Cannabinoids-1) IMMUNALYSIS DIRECT ELISA Kit for Forensic Matrices

    Synthetic Cannabinoids-1) IMMUNALYSIS DIRECT ELISA Kit for Forensic Matrices

    K2 (Synthetic IMMUNALYSIS Cannabinoids-1) DIRECT ELISA Kit for forensic matrices JWH-018 Demonstrates significant cross reactivity with the major metabolites of JWH-018, JWH-073, Schedule I Controlled Substances: JWH-018, JWH-073, JWH-200, JWH-019, JWH-200 and AM-2201. JWH-122, JWH-398, JWH-081, JWH-250, JWH-203 CP-47,497, CP-47,497 C8, HU-210, HU-211, AM-2201, AM-694, RCS-4 (SR-19), RCS-8 (SR-18) Street Names: Spice, K2, Genie, Yucatan Fire, Skunk, Sence, Smoke, ChillX, Highdi’s Almdröhner, Earth Impact, Gorillaz, Galaxy Gold, Space Truckin, Solar Flare, Moon Rocks, Blue Lotus, Aroma, Scope, Sky, OG Potpourri, Bliss, Black Momba, Bombay Blue, Fake Weed, and Zohai. Urine About Synthetic Cannabinoids: Spice or K2 is a mixture of herbs and spices treated with synthetic compounds similar to THC that is typically sold in head shops, tobacco shops or over the internet. Though not structurally related, K2 mimics the psychoactive stimulant properties of THC but can be 100 to 800 times more potent than THC.1 Administration: Synthetic Cannabinoid products are usually smoked in joints or pipes, and sometimes made into tea.2 Effects: Psychological effects are similar to those of marijuana and include paranoia, panic attacks and giddiness. Physiological effects include increased heart rate and high blood pressure. Long-term effects are not known.2 1. Devane, W. A. et al. A novel probe for the cannabi- noid receptor. Journal of Medical Chemistry 35 (11): 2065–2069 (1992). 2. Drug Enforcement Administration; www.dea.gov. Tel 909.482.0840 | Toll Free
  • 1 Reactive Methylene Compounds As Synthons for Various Bio Active

    1 Reactive Methylene Compounds As Synthons for Various Bio Active

    Reactive methylene compounds as synthons for various bio active molecules Mohd. Shahnawaz khan1*, Saba Parveen Siddiqui2, Daya S. Seth3 1Department of Chemistry, JK. Lakshmipat University Jaipur (Raj) -302026, India 2Department of Chemistry Kendriya Vidhayalaya N0-1 Pratap Nagar, Udaipur (Raj) 313001, India 3Department of Chemistry, School of Chemical Sciences, St. John's College, Agra (UP)-282002, India *E-mail: [email protected] Abstract: Novel malonamic acid, hydrazide and amide were efficiently synthesized from the condensation of 3-NO2 aniline with diethyl malonate. Also the synthesis of coumarins, azo coumarins. benzocoumarins, cinnamamide, and α:β-unsaturated acid, were achieved by the reaction of above synthesized compounds in a single step reaction in good to excellent yields. And these eight compounds were tested for their antibacterial activities with two bacteria E. coli and S. aureus. Compounds are showing slightly to moderate antibacterial activities against same bacterias. Key words: Reactive methylene compounds, antibacterial activity. Introduction: Organic compounds containing the reactive methylene group provide excellent intermediates in synthetic organic chemistry. Such substances have been found to be useful as synthons for various bioactive agents. Using such type of compounds as starting material quiet a large number of heterocyclic and non-heterocyclic compounds can be prepared by condensing them with other substances. Heterocycles form by far the largest of classical divisions of organic chemistry. A broad spectrum of biological activity associated with heterocyclic compounds has attracted interest in drug discovery research. As evident from literature, both synthetic as well as natural oxygen and nitrogen containing heterocyclic molecules possesses significant antimicrobial activities and a large number have been made up to clinics for health care worldwide.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • United States Patent (19) 11 Patent Number: 4,880,935 Thorpe 45 Date of Patent: Nov

    United States Patent (19) 11 Patent Number: 4,880,935 Thorpe 45 Date of Patent: Nov

    United States Patent (19) 11 Patent Number: 4,880,935 Thorpe 45 Date of Patent: Nov. 14, 1989 (54. HETEROBIFUNCTIONAL LINKING Wang et al., Israel Journal of Chem., vol. 12, 1974, pp. AGENTS DERVED FROM 375-389. N-SUCCNMDO-DTHO-ALPHIA Vallero et al., Science, 222, 1983, pp. 512-515. METHYL-METHYLENE-BENZOATES Camber et al., Method of Enzymol, 112, 1985, pp. 201-225. 75 Inventor: Philip E. Thorpe, London, England Langone et al., Method of Enzymol, 93, 1983, p. 280. Masuho et al., J. Biochem, 91, 1982, pp. 1583-1591. 73 Assignee: ICRF (Patents) Limited, London, Carlsson et al., Biochem. J., 1978, 173, pp. 723-737. England Calombatti et al., J. Immunol, 131, 1983, pp. 3091-3095. Brown et al., Cancer Res., vol. 45, 1985, pp. 1214-1221. 21 Appl. No.: 90,386 Ramakrishnonet al., Cancer Res., 44, 1984, pp. 201-208. 22 Filed: Aug. 27, 1987 Gras et al., J. of Immunol Methods, 81, 1985, pp. 283-297. Related U.S. Application Data Primary Examiner-Alan L. Rotman Attorney, Agent, or Firm-Nixon & Vanderhye 63 Continuation of Ser. No. 884,641, Jul 11, 1986, aban doned. (57 ABSTRACT The efficacy of immunotoxins having an antibody that 51) Int. Cl.".................. C07D 207/46; CO7D 207/48; recognizes a tumour associated antigen linked to a cyto CO7D 401/12 toxin through a heterobifunctional agent of the disul 52 U.S. Cl. ..................................... 546/281; 548/542 phide type is improved by providing in the heterobi 58 Field of Search ......................... 548/542; 546/281 functional agent a molecular grouping creating steric 56 References Cited hindrance in relation to the disulphide link.
  • Booklet 4 Stimulants Preface

    Booklet 4 Stimulants Preface

    4 STIMULANTS 4 STIMULANTS 2019 2019 © United Nations, June 2019. All rights reserved worldwide. ISBN: 978-92-1-148314-7 eISBN: 978-92-1-004174-4 United Nations publication, Sales No. E.19.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: www.unodc.org/wdr2019 PREFACE The findings of this year’s World Drug Report fill in same time clamping down on organized crime and and further complicate the global picture of drug trafficking.
  • Toxicology Report Division of Toxicology Daniel D

    Toxicology Report Division of Toxicology Daniel D

    Franklin County Forensic Science Center Office of the Coroner Anahi M. Ortiz, M.D. 2090 Frank Road Columbus, Ohio 43223 Toxicology Report Division of Toxicology Daniel D. Baker, Chief Toxicologist Casey Goodson Case # LAB-20-5315 Date report completed: January 28, 2021 A systematic toxicological analysis has been performed and the following agents were detected. Postmortem Blood: Gray Top Thoracic ELISA Screen Acetaminophen Not Detected ELISA Screen Barbiturates Not Detected ELISA Screen Benzodiazepines Not Detected ELISA Screen Benzoylecgonine Not Detected ELISA Screen Buprenorphine Not Detected ELISA Screen Cannabinoids See Confirmation ELISA Screen Fentanyl Not Detected ELISA Screen Methamphetamine Not Detected ELISA Screen Naltrexone/Naloxone Not Detected ELISA Screen Opiates Not Detected ELISA Screen Oxycodone/Oxymorphone Not Detected ELISA Screen Salicylates Not Detected ELISA Screen Tricyclics Not Detected Page 1 of 4 Casey Goodson Case # LAB-20-5315 GC/FID Ethanol Not Detected GC/MS Acidic/Neutral Drugs None Detected GC/MS Nicotine Positive GC/MS Cotinine Positive Reference Lab Delta-9-THC 13 ng/mL Reference Lab 11-Hydroxy-Delta-9-THC 1.2 ng/mL Reference Lab 11-Nor-9-Carboxy-Delta-9-THC 15 ng/mL Postmortem Urine: Gray Top Urine GC/MS Cotinine Positive This report has been verified as accurate and complete by ______________________________________ Daniel D. Baker, M.S., F-ABFT Cannabinoid quantitations in blood were performed by NMS Labs, Horsham, PA. Page 2 of 4 Casey Goodson Case # LAB-20-5315 Postmortem Toxicology Scope of Analysis Franklin County Coroner’s Office Division of Toxicology Enzyme Linked Immunosorbant Assay (ELISA) Blood Screen: Qualitative Presumptive Compounds/Classes: Acetaminophen (cut-off 10 µg/mL), Benzodiazepines (cut-off 20 ng/mL), Benzoylecgonine (cut-off 50 ng/mL), Cannabinoids (cut-off 40 ng/mL), Fentanyl (cut-off 1 ng/mL), Methamphetamine/MDMA (cut-off 50 ng/mL), Opiates (cut-off 40 ng/mL), Oxycodone/Oxymorphone (cut-off 40 ng/mL), Salicylates (50 µg/mL).
  • Virginia Acts of Assembly -- 2021 Special Session I

    Virginia Acts of Assembly -- 2021 Special Session I

    VIRGINIA ACTS OF ASSEMBLY -- 2021 SPECIAL SESSION I CHAPTER 110 An Act to amend and reenact §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia, relating to industrial hemp; emergency. [H 2078] Approved March 12, 2021 Be it enacted by the General Assembly of Virginia: 1. That §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia are amended and reenacted as follows: § 3.2-4112. Definitions. As used in this chapter, unless the context requires a different meaning: "Cannabis sativa product" means a product made from any part of the plant Cannabis sativa, including seeds thereof and any derivative, extract, cannabinoid, isomer, acid, salt, or salt of an isomer, whether growing or not, with a concentration of tetrahydrocannabinol that is greater than that allowed by federal law. "Deal" means to buy temporarily possess industrial hemp grown in compliance with state or federal law and to sell such industrial hemp to a person who that (i) processes industrial hemp in compliance with state or federal law or has not been processed and (ii) sells industrial hemp to a person who processes industrial hemp in compliance with state or federal law was not grown and will not be processed by the person temporarily possessing it.
  • Synthetic Cannabinoids (60 Substances) A) Classical Cannabinoid

    Synthetic Cannabinoids (60 Substances) A) Classical Cannabinoid

    Synthetic cannabinoids (60 substances) a) Classical cannabinoid OH H OH H O Common name Chemical name CAS number Molecular Formula HU-210 3-(1,1’-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1- Synonym: 112830-95-2 C H O hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol 25 38 3 11-Hydroxy-Δ-8-THC-DMH b) Nonclassical cannabinoids OH OH R2 R3 R4 R1 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyloctan- 2- yl) CP-47,497 70434-82-1 C H O CH H H H phenol 21 34 2 3 rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylheptan- 2- yl) CP-47,497-C6 - C H O H H H H phenol 20 32 2 CP-47,497-C8 rel-2- [(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylnonan- 2- yl) 70434-92-3 C H O C H H H H Synonym: Cannabicyclohexanol phenol 22 36 2 2 5 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyldecan- 2- yl) CP-47,497-C9 - C H O C H H H H phenol 23 38 2 3 7 rel-2- ((1 R,2 R,5 R)-5- hydroxy- 2- (3- hydroxypropyl)cyclohexyl)- 3-hydroxy CP-55,940 83003-12-7 C H O CH H H 5-(2- methyloctan- 2- yl)phenol 24 40 3 3 propyl rel-2- [(1 S,3 R)-3- hydroxy-5,5-dimethylcyclohexyl]- 5- (2- Dimethyl CP-47,497-C8 - C H O C H CH CH H methylnonan-2- yl)phenol 24 40 2 2 5 3 3 c) Aminoalkylindoles i) Naphthoylindoles 1' R R3' R2' O N CAS Molecular Common name Chemical name R1’ R2’ R3’ number Formula [1-[(1- methyl- 2- piperidinyl)methyl]- 1 H-indol- 3- yl]- 1- 1-methyl-2- AM-1220 137642-54-7 C H N O H H naphthalenyl-methanone 26 26 2 piperidinyl